These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15565298)

  • 1. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain.
    Hampel H; Haslinger A; Scheloske M; Padberg F; Fischer P; Unger J; Teipel SJ; Neumann M; Rosenberg C; Oshida R; Hulette C; Pongratz D; Ewers M; Kretzschmar HA; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):269-78. PubMed ID: 15565298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease.
    Hampel H; Teipel SJ; Padberg F; Haslinger A; Riemenschneider M; Schwarz MJ; Kötter HU; Scheloske M; Buch K; Stübner S; Dukoff R; Lasser R; Müller N; Sunderland T; Rapoport SI; Möller HJ
    Brain Res; 1999 Mar; 823(1-2):104-12. PubMed ID: 10095017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study.
    Bagli M; Papassotiropoulos A; Hampel H; Becker K; Jessen F; Bürger K; Ptok U; Rao ML; Möller HJ; Maier W; Heun R
    Eur Arch Psychiatry Clin Neurosci; 2003 Feb; 253(1):44-8. PubMed ID: 12664314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease.
    Li R; Strohmeyer R; Liang Z; Lue LF; Rogers J
    Neurobiol Aging; 2004 Sep; 25(8):991-9. PubMed ID: 15212823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain.
    Stephenson DT; Lemere CA; Selkoe DJ; Clemens JA
    Neurobiol Dis; 1996 Feb; 3(1):51-63. PubMed ID: 9173912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis.
    Kumar U
    Neuroscience; 2005; 134(2):525-38. PubMed ID: 15961235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the interleukin 6 system in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb.
    Shu HF; Zhang CQ; Yin Q; An N; Liu SY; Yang H
    J Neuropathol Exp Neurol; 2010 Aug; 69(8):838-49. PubMed ID: 20613633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia.
    Cacabelos R; Alvarez XA; Fernández-Novoa L; Franco A; Mangues R; Pellicer A; Nishimura T
    Methods Find Exp Clin Pharmacol; 1994 Mar; 16(2):141-51. PubMed ID: 8007743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional mosaic genomic heterogeneity in the elderly and in Alzheimer's disease as a correlate of neuronal vulnerability.
    Arendt T; Brückner MK; Lösche A
    Acta Neuropathol; 2015 Oct; 130(4):501-10. PubMed ID: 26298468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Density of Sgt1-immunopositive neurons is decreased in the cerebral cortex of Alzheimer's disease brain.
    Spiechowicz M; Bernstein HG; Dobrowolny H; Leśniak W; Mawrin C; Bogerts B; Kuźnicki J; Filipek A
    Neurochem Int; 2006 Oct; 49(5):487-93. PubMed ID: 16698122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease.
    Culpan D; Prince JA; Matthews S; Palmer L; Hughes A; Love S; Kehoe PG; Wilcock GK
    Neurosci Lett; 2006 Nov; 408(2):141-5. PubMed ID: 16973274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease.
    Hampel H; Sunderland T; Kötter HU; Schneider C; Teipel SJ; Padberg F; Dukoff R; Levy J; Möller HJ
    Brain Res; 1998 Jan; 780(2):356-9. PubMed ID: 9507194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
    Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
    Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients.
    Strauss S; Bauer J; Ganter U; Jonas U; Berger M; Volk B
    Lab Invest; 1992 Feb; 66(2):223-30. PubMed ID: 1370967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
    Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
    Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered NCAM expression associated with the cholinergic system in Alzheimer's disease.
    Aisa B; Gil-Bea FJ; Solas M; García-Alloza M; Chen CP; Lai MK; Francis PT; Ramírez MJ
    J Alzheimers Dis; 2010; 20(2):659-68. PubMed ID: 20164549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy.
    Reinikainen KJ; Soininen H; Riekkinen PJ
    J Neurosci Res; 1990 Dec; 27(4):576-86. PubMed ID: 1981917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex.
    Walker DG; Whetzel AM; Serrano G; Sue LI; Beach TG; Lue LF
    Neurobiol Aging; 2015 Feb; 36(2):571-82. PubMed ID: 25448602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients.
    März P; Heese K; Hock C; Golombowski S; Müller-Spahn F; Rose-John S; Otten U
    Neurosci Lett; 1997 Dec; 239(1):29-32. PubMed ID: 9547164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia.
    Du AT; Schuff N; Kramer JH; Rosen HJ; Gorno-Tempini ML; Rankin K; Miller BL; Weiner MW
    Brain; 2007 Apr; 130(Pt 4):1159-66. PubMed ID: 17353226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.